330 related articles for article (PubMed ID: 26153518)
21. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
Huidekoper HH; Vaz FM; Verrips A; Bosch AM
Eur J Pediatr; 2016 Jan; 175(1):143-6. PubMed ID: 26156051
[TBL] [Abstract][Full Text] [Related]
22. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
[TBL] [Abstract][Full Text] [Related]
23. Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.
de Sain-van der Velden MG; Verrips A; Prinsen BH; de Barse M; Berger R; Visser G
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S387-93. PubMed ID: 18949577
[TBL] [Abstract][Full Text] [Related]
24. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults.
Mandia D; Chaussenot A; Besson G; Lamari F; Castelnovo G; Curot J; Duval F; Giral P; Lecerf JM; Roland D; Pierdet H; Douillard C; Nadjar Y
J Neurol; 2019 Aug; 266(8):2043-2050. PubMed ID: 31115677
[TBL] [Abstract][Full Text] [Related]
25. Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes.
Appadurai V; DeBarber A; Chiang PW; Patel SB; Steiner RD; Tyler C; Bonnen PE
Mol Genet Metab; 2015 Dec; 116(4):298-304. PubMed ID: 26643207
[TBL] [Abstract][Full Text] [Related]
26. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.
Batta AK; Salen G; Tint GS
Metabolism; 2004 May; 53(5):556-62. PubMed ID: 15131757
[TBL] [Abstract][Full Text] [Related]
27. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.
Salen G; Grundy SM
J Clin Invest; 1973 Nov; 52(11):2822-35. PubMed ID: 4355999
[TBL] [Abstract][Full Text] [Related]
28. A novel pathway for biosynthesis of cholestanol with 7 alpha-hydroxylated C27-steroids as intermediates, and its importance for the accumulation of cholestanol in cerebrotendinous xanthomatosis.
Skrede S; Björkhem I; Buchmann MS; Hopen G; Fausa O
J Clin Invest; 1985 Feb; 75(2):448-55. PubMed ID: 3919058
[TBL] [Abstract][Full Text] [Related]
29. On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis.
Panzenboeck U; Andersson U; Hansson M; Sattler W; Meaney S; Björkhem I
J Lipid Res; 2007 May; 48(5):1167-74. PubMed ID: 17325385
[TBL] [Abstract][Full Text] [Related]
30. The value of surrogate markers to monitor cholesterol absorption, synthesis and bioconversion to bile acids under lipid lowering therapies.
Stellaard F; von Bergmann K; Sudhop T; Lütjohann D
J Steroid Biochem Mol Biol; 2017 May; 169():111-122. PubMed ID: 27060336
[TBL] [Abstract][Full Text] [Related]
31. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.
Salen G; Berginer V; Shore V; Horak I; Horak E; Tint GS; Shefer S
N Engl J Med; 1987 May; 316(20):1233-8. PubMed ID: 3106810
[TBL] [Abstract][Full Text] [Related]
32. Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.
Koyama S; Sekijima Y; Ogura M; Hori M; Matsuki K; Miida T; Harada-Shiba M
J Atheroscler Thromb; 2021 Sep; 28(9):905-925. PubMed ID: 33967188
[TBL] [Abstract][Full Text] [Related]
33. Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.
Catarino CB; Vollmar C; Küpper C; Seelos K; Gallenmüller C; Bartkiewicz J; Biskup S; Hörtnagel K; Klopstock T
J Neurol; 2018 Feb; 265(2):388-393. PubMed ID: 29260356
[TBL] [Abstract][Full Text] [Related]
34. Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment.
Alhariri A; Hamilton K; Oza V; Cordoro K; Sobreira NL; Malloy M; Slavotinek A
Am J Med Genet A; 2017 Aug; 173(8):2275-2279. PubMed ID: 28590052
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis.
Duell PB; Salen G; Eichler FS; DeBarber AE; Connor SL; Casaday L; Jayadev S; Kisanuki Y; Lekprasert P; Malloy MJ; Ramdhani RA; Ziajka PE; Quinn JF; Su KG; Geller AS; Diffenderfer MR; Schaefer EJ
J Clin Lipidol; 2018; 12(5):1169-1178. PubMed ID: 30017468
[TBL] [Abstract][Full Text] [Related]
36. Accumulation of 7 alpha-hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: effect of treatment with chenodeoxycholic acid.
Björkhem I; Skrede S; Buchmann MS; East C; Grundy S
Hepatology; 1987; 7(2):266-71. PubMed ID: 3557306
[TBL] [Abstract][Full Text] [Related]
37. Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis.
Burnett JR; Moses EA; Croft KD; Brown AJ; Grainger K; Vasikaran SD; Leitersdorf E; Watts GF
Clin Chim Acta; 2001 Apr; 306(1-2):63-9. PubMed ID: 11282095
[TBL] [Abstract][Full Text] [Related]
38. [Cerebrotendinous xanthomatosis, a treatable metabolic disorder].
Heller R; Grau AJ; Schäbitz WR; Schwaninger M
Nervenarzt; 2002 Dec; 73(12):1160-6. PubMed ID: 12486565
[TBL] [Abstract][Full Text] [Related]
39. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
Dotti MT; Lütjohann D; von Bergmann K; Federico A
Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
[TBL] [Abstract][Full Text] [Related]
40. On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase.
Båvner A; Shafaati M; Hansson M; Olin M; Shpitzen S; Meiner V; Leitersdorf E; Björkhem I
J Lipid Res; 2010 Sep; 51(9):2722-30. PubMed ID: 20511491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
